SynAct Pharma Names James Knight as Chief Business Officer - Already published in Swedish today
SynAct Pharma AB (“SynAct”) today announced the appointment of James Knight as Chief Business Officer (CBO). He will head up business development and pipeline portfolio management and has more than 25 years of experience in the biopharmaceutical industry. Mr. Knight brings highly relevant experience and skills to the SynAct team as it advances its lead selective melanocortin asset AP1189 through Phase 2a clinical proof of concept trials. Uppdaterad 2021-02-11 Publicerad 2021-02-11
James was formally the VP of Portfolio Strategy at Questcor Pharmaceuticals where he was responsible for leading the expansion of Acthar Gel from two promoted indications in two specialty audiences to nine promoted indications in five specialty areas including rheumatology. Questcor’s success in expanding Acthar use led to its acquisition by Mallinck